Related Experiment Video

Updated: Apr 23, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.6K

Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy

C H Latta1, H M Brothers2, D M Wilcock2

  • 1University of Kentucky, Sanders-Brown Center on Aging, Department of Physiology, Lexington, KY 40536, USA; The University of Manchester, Department of Biology, Manchester M13 9PL, United Kingdom.

Neuroscience
|October 7, 2014
PubMed

Insights

Neuroinflammation is a key factor in Alzheimer's disease (AD). Understanding the diverse roles and heterogeneity of the brain's inflammatory response is crucial for developing personalized AD treatments.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Neuroinflammation is a known hallmark of Alzheimer's disease (AD), with microglia observed around amyloid plaques since its initial description.
  • Recent advancements have significantly improved the understanding of neuroinflammation's complex and varied roles in neurodegenerative disorders like AD.

Purpose of the Study:

  • To review the multifaceted roles of neuroinflammation in Alzheimer's disease.
  • To explore how the heterogeneity of individual inflammatory responses can inform therapeutic development and personalized treatment strategies for AD.

Main Methods:

  • This is a review article, synthesizing existing research and literature on neuroinflammation in Alzheimer's disease.
  • The focus is on analyzing the complexities and diverse functions of the inflammatory response in the context of AD.

Main Results:

  • While knowledge gaps and conflicting data persist, there is a vastly improved understanding of neuroinflammation's complex functions in AD.
  • The heterogeneity of inflammatory responses presents opportunities for targeted therapeutic development.

Conclusions:

  • Understanding the diverse and heterogeneous nature of neuroinflammation is essential for advancing Alzheimer's disease research.
  • Personalizing treatment strategies based on individual inflammatory profiles holds promise for more effective AD therapies.
Keywords:
Alzheimer’samyloidcytokinesinflammationmicrogliaphenotypes

More Related Videos

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.7K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

10.1K

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
10
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
10
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.5K